Fadda Giulia, Campus Guglielmo, Lugliè PierFranca
Dental Institute, University of Sassari, Viale San Pietro 43/c I-07100 Sassari, Italy.
BMC Oral Health. 2006 Oct 18;6:13. doi: 10.1186/1472-6831-6-13.
We describe the risk indicators for oral mucositis (OM) in paediatric oncology patients hospitalised in the Institut Gustave Roussy (Villejuif-Paris) and treated with alkylant chemotherapy with autologous peripheral blood progenitor cells.
The sample was selected using PIGAS software. Three groups of subjects received different chemotherapy regimens: A. Melphalan, B. Busulfan and C. other alkylant protocols. The degree of mucositis was recorded by CTC version 2.0 (Common Toxicity Criteria). Descriptive statistics were performed. The association between mucositis and risk indicator variables was tested using a chi2 test. The association between case status and covariates was tested using unconditional logistic regression analysis.
Of the 337 children enrolled, 241 showed mucositis (group 1) and 96 did not show mucositis (group 2) during alkylant chemotherapy. There was a higher prevalence of male patients in both groups. The three different chemotherapy regimen groups are correlated with the appearance of oral mucositis (chi2 = 22.42, p < 0.01). Weight loss was higher in group 1 (chi2 = 6.31, p = 0.01). The duration of aplasia was lower in the Busulfan protocol (7.5 days) than in the Melphalan group (9.3 days) or the other regimens (8.6 days). The use of Bufulfan was directly associated with case status (presence of oral mucositis): odds ratio [OR] = 2.1 and confidence interval [95%CI] = 1.3-3.0. Also, occurrences of germinal tumours and secondary bacterial infections were directly linked with case status: [OR] = 1.4 and 1.8, confidence interval [95%CI] = 1.2 - 1.7 and 1.1 - 2.5, respectively.
The presence of OM was associated with the three different chemotherapy regimens considered; in particularly patients treated with Busulfan had the highest prevalence.
我们描述了在古斯塔夫·鲁西研究所（维勒瑞夫 - 巴黎）住院并接受烷化剂化疗及自体外周血祖细胞治疗的儿科肿瘤患者口腔黏膜炎（OM）的风险指标。
使用PIGAS软件选取样本。三组受试者接受不同的化疗方案：A. 美法仑，B. 白消安，C. 其他烷化剂方案。口腔黏膜炎程度通过CTC 2.0版（通用毒性标准）记录。进行描述性统计。使用卡方检验测试黏膜炎与风险指标变量之间的关联。使用无条件逻辑回归分析测试病例状态与协变量之间的关联。
在337名登记的儿童中，241名在烷化剂化疗期间出现口腔黏膜炎（第1组），96名未出现口腔黏膜炎（第2组）。两组中男性患者的患病率均较高。三种不同的化疗方案组与口腔黏膜炎的出现相关（卡方 = 22.42，p < 0.01）。第1组体重减轻更明显（卡方 = 6.31，p = 0.01）。白消安方案的再生障碍期持续时间（7.5天）低于美法仑组（9.3天）或其他方案组（8.6天）。白消安的使用与病例状态（口腔黏膜炎的存在）直接相关：比值比[OR] = 2.1，置信区间[95%CI] = 1.3 - 3.0。此外，生殖细胞瘤和继发性细菌感染的发生与病例状态直接相关：[OR] = 1.4和1.8，置信区间[95%CI]分别为1.2 - 1.7和1.1 - 2.5。
口腔黏膜炎的存在与所考虑的三种不同化疗方案相关；特别是接受白消安治疗的患者患病率最高。
